64.18
+0.89(+1.41%)
Currency In USD
| Previous Close | 63.29 |
| Open | 63.39 |
| Day High | 65.28 |
| Day Low | 63.2 |
| 52-Week High | 70.98 |
| 52-Week Low | 29.31 |
| Volume | 1.15M |
| Average Volume | 1.98M |
| Market Cap | 7.64B |
| PE | -10.19 |
| EPS | -6.3 |
| Moving Average 50 Days | 62.73 |
| Moving Average 200 Days | 45.59 |
| Change | 0.89 |
If you invested $1000 in Cytokinetics, Incorporated (CYTK) 10 years ago, it would be worth $6,194.98 as of December 25, 2025 at a share price of $64.18. Whereas If you bought $1000 worth of Cytokinetics, Incorporated (CYTK) shares 5 years ago, it would be worth $3,063.48 as of December 25, 2025 at a share price of $64.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
GlobeNewswire Inc.
Dec 19, 2025 9:00 PM GMT
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor Conference
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Dec 17, 2025 12:30 PM GMT
Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics,
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Dec 12, 2025 1:42 PM GMT
Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of t